Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above

British Journal of Haematology

Volumn 93, Issue 1, 1996, Pages 89-95

  Delima, Marcos ^a   Ghaddar, Habib ^a   Pierce, Sherry ^a   Estey, Elihu ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

age 80+; AML; treatment

Indexed keywords

CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYTARABINE; DAUNORUBICIN; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MEDICAL FUTILITY; PROBABILITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029916143     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.4771012.x     Document Type: Article

References (26)

1. Baudard, M., Marie, J., Cadiou, M. & Vigvie, F. (1994) Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. British Journal of Haematology, 86, 82-91.
2. Brincker, H. (1982) Population-based age- and sex-specific incidence rates in the four main types of leukaemia. Scandinavian Journal of Haematology, 29, 241-249.
3. Brincker, H. (1985) Estimate of overall treatment results in acute nonlymphocytic leukemia based on age specific rates of incidence and of complete remission. Cancer Treatment Reports, 69, 5-11.
4. Buchner, T., Hiddermann, W., Maschmeyer, G., Ludwig, W.D., Aul, C. & Lathan, B. (1992) AML in patients of 60+ years: full versus reduced dose induction: randomized study by AMLCG. (Abstract). Blood, 80, (Suppl. 1), 209a.
5. Dutcher, J., Strauman, J. & Wiernik, P. (1984) Treatment of acute non-lymphocytic leukemia in patients older than 60 years of age. (Abstract). Blood, 64, (Suppl. 1), 163a.
6. Estey, K., Dixon, D., Kantarjian, H., Keating, M.J., McCredie, K., Bodey, G.P., Kurzrock, R., Talpaz, M. & Freireich, E.J. (1990) Treatment of poor-prognosis, newly-diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte macrophage colony-stimulating factor. Blood, 75, 1766-1769.
7. Estey, E., Kantarjian, H. & Keating, M. (1993) Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Seminars in Oncology, 20, (Suppl. 8), 1-5.
8. Estey, E., Smith, T., Keating, M.J., McCredie, K.B., Gehan, E.A. & Freireich, E.J. (1989) Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia, 3 257-263.
9. Estey, K., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L.E., Koller, C. & Kornblau, S. (1994) Use of G-CSF before, during, and after fludurabine + ara-C induction therapy of newly-diagnosed AML or MDS: comparison with fludarabine + ara-C without CSF. Journal of Clinical Oncology, 12, 671-678.
10. Estey, E., Thall, P., Kantarjian, H., O'Brien, S., Koller, C.A., Beran, M., Gutterman, J., Deisseroth, A.B. & Keating, M.J. (1992) Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood, 79, 2246-2255.
11. Freireich, E., Gehan, E. & Sulman, D. (1961) The effect of chemotherapy on acute leukemia in the human. Journal of Chronic Diseases, 14, 593-608.
12. Ghaddar, H., Plunkett, W., Kantarjian, H.M., Piere, S., Freireich, E.J., Keating, M.Z.J. & Estey, E.H. (1994) Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous infusion high-dose cylosine arabinoside. Leukemia, 8, 1269-1284.
13. Johnson, P., Hunt, L. & Liu Yin, J.A. (1993) Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. British Journal of Haematology, 85, 300-306.
14. Kahn, S.B., Begg, C.B., Mazza, J.J., Bennett, J.M., Bonner, H. & Glick, J.H. (1984) Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. Journal of Clinical Oncology, 2, 865.
15. Kahn, S.B., Ebrahim, K., Cassileth, P., Bennett, T.M., Knospe, W.H. & O'Connell, M.J. (1989) Attenuated high-dose cytosine arabinoside in the treatment of the elderly patient with acute nonlymphocytic leukemia: an Eastern Cooperative Oncology Group pilot study. American Journal of Clinical Oncology, 12, 201-204.
16. Keating, M., Smith, T., Kantarjian, H., Cork, A., Walters, R., Trujillo, J.M. & McCredie, K.B. (1988) Cytogenetic pattern in acture myelogenous leukemia: a major reproducible determinant of outcome. Leukemia, 2, 403-413.
17. Liu Yin, J.A., Johnson, P.R., Davis, J.M. Flanagan, N.G., Gorst, D.W. & Lewis, M.J. (1991) Mitoxantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. British Journal of Haematology, 79, 415-420.
18. Lowenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Gucnie, C.H., Peetermans, M., Gibu, G., Suciu, S. & Stryckmanns, P. (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. Journal of Clinical Oncology, 7, 1268-1274.
19. Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R., Frei, E., III (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine, 10, 896-903.
20. Preisler, H.D. (1978) Failure of remission induction in acute myelocytic leukemia. Medical and Pediatric Oncology, 4, 275-280.
21. 2 in 2 × 2 contingency tables. Journal of the American Statistics Association, 75, 386-394.
22. Sebban, C., Archimbaud, H., Coiffier, B., Guyotat, D., Treille-Riotovet, D., Maupas, J. & Fiere, D. (1988) Treatment of acute myeloid leukemia in elderly patients: a retrospective study. Cancer, 61, 227-231.
23. Shepherd, J.D., Reece, D.E., Barnett, M.J., Klingermann, H.-G., Nantel, S.H., Sutherland, H.J. & Philips, G.L. (1993) Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide. Leukemia and Lymphoma, 9, 211-215.
24. Tilly, H., Castaigne, S., Bordessoule, D., Csassus, P., Leprise, P., Tertin, N.G., Desablens, B., Henry-Amar, M. & Degos, L. (1990) Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. Journal of Clinical Oncology, 8, 272-279.
25. Weick, J., Kopecky, K., Appelbaum, F., Head, D., Elias, L., Kingsbury, L., Daniels, D., Balcerzak, S.P., Mills, G.M., Hynes, H.E., Coltman, C. & Grever, M. (1992) A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with acute myelogenous leukemia. (Abstract). Proceedings of the American Society of Clinical Oncology, 11, 261.
26. Zubrod, C.G., Schneiderman, M., Frei, K., Brindley, C., Gold, G.L., Shneider, B., Oviedo, R., Gorman, J., Jones, R., Jonsson, V., Colsky, J., Chalmers, T., Ferguson, W., Lasagna, L. & Owens, A.H. (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and trimethylene thioposphoramide. Journal of Chronic Diseases, 11, 7-33.